WE SUSTAIN ADDED VALUES

Management report as of June 30, 2025

Vitruvia Medical AG achieved results in line with expectations in the first half of 2025. The Board of Directors confirms its forecast for the full year.

Vitruvia Medical AG is on track for the first six months of 2025. The result was slightly down at CHF -72,889.88 compared to CHF -53,388.06 in the previous year. Based on the expected results for the first half of 2025, the company's management confirms its outlook for the current full year.

LT technologies GmbH & Co. KG, a wholly owned subsidiary of Vitruvia Medical AG, can look back on a strong first half of 2025. The half-year revenue target of €1,220,000 was achieved as planned, putting the company on track to meet its annual target of €2.4 million.

A significant achievement in July was the successful recertification according to DIN EN ISO 13485:2021. This underscores the company's high quality standards and reliable process structure – a clear signal to customers, partners, and the market.

The collaboration with a German full-service provider has established itself as a sustainable partnership and is being continuously strengthened. There is also clear momentum on the customer side: sales growth was achieved primarily with existing customers, who are increasingly relying on LT's cost-effective solutions—especially in light of the current financial challenges in the hospital sector.

This situation also offers opportunities: The cost efficiency and service orientation of LT technologies GmbH & Co. KG come into play where hospitals are forced to leverage savings potential – without compromising on quality or performance.

Another growth driver is the increased cooperation with an Austrian company, which already led to significant sales increases in the first half of the year. The cooperation will be further developed strategically in order to exploit the potential in the long term.

Sustainability remains a key issue for the future. Growing environmental awareness and a shift in thinking within the healthcare sector are in line with the company's strategy. LT offers sustainable solutions that are not only ecologically sound but also economically advantageous: clinics reduce their expenses, maintain their performance, and at the same time make a positive contribution to environmental protection.

Outlook:
With clear goals, strong partnerships, and a consistently sustainable approach, LT technologies GmbH & Co. KG is ideally positioned to make the second half of 2025 a success and further strengthen its position in the market.
In addition to the encouraging development of its investment in LT technologies GmbH & Co. KG, Vitruvia Medical AG continues to look for interesting acquisition opportunities to expand its portfolio.

Anglikon, August 1st, 2025

Vitruvia Medical AG

Vitruvia Medical AG - Kesselackerstrasse 18 - CH-5611 Anglikon - Tel. +41 44 915 33 78 - Mail: kontakt@vitruvia-med.com - Web: www.vitruvia-med.com
Handelsregisteramt des Kantons Aargau - UID Nr. CHE-363.832.344
Luzerner Kantonalbank AG - CH-6003 Luzern - BIC: LUKBCH2260A - IBAN: CH07 0077 8220 8311 4200 1

Bilanz per 30. Juni 2025

	30.06.25 CHF	30.06.24 CHF
AKTIVEN		
Umlaufvermögen		
Flüssige Mittel	2'030.31	1'866.56
Forderungen ggn. Tochtergesellschaften	0.00	0.00
Sonstige Forderungen	2'046.45	1'946.45
Aktive Rechnungsabgrenzungen	0.00	0.00
	4'076.76	**3'813.01**
Anlagevermögen		
langfristige Finanzanlagen	236'750.00	245'562.50
Beteiligungen	1'607'819.00	1'607'819.00
	1'844'569.00	**1'853'381.50**
TOTAL AKTIVEN	**1'848'645.76**	**1'857'194.51**
PASSIVEN		
Kurzfristiges Fremdkapital		
Verbindlichkeiten aus Lieferungen und Leistungen	4'602.36	1'638.36
Verbindlichkeiten ggn. Nahestehende	60'000.00	20'000.00
kurzfristige Finanzverbindlichkeiten	0.00	1.82
Passive Rechnungsabgrenzungen	83'355.12	41'620.00
	147'957.48	**63'260.18**
Langristiges Fremdkapital		
Wandelanleihe - 2% 2022 - 2025	1'255'000.00	1'155'000.00
	1'255'000.00	**1'155'000.00**
Eigenkapital		
Aktienkapital	2'511'578.00	2'511'578.00
Reserven aus Kapitaleinlagen	10'979'786.25	10'979'786.25
Verlustvortrag	-12'972'786.09	-12'799'041.86
Jahresverlust	-72'889.88	-53'388.06
	445'688.28	**638'934.33**
TOTAL PASSIVEN	**1'848'645.76**	**1'857'194.51**

Erfolgsrechnung
1. Januar 2025 bis 30. Juni 2025
Vorjahr 1. Januar 2024 bis 30. Juni 2024

	2024 CHF	2024 CHF
Verwaltungsaufwand		
Verwaltungsaufwand	0.00	0.00
Rechts- und Beratungsaufwand	4'677.00	5'727.15
Organisationskosten	17'521.27	16'539.66
Büro- und Verwaltungskosten	6'807.87	8'073.72
	29'006.14	**30'340.53**
Finanzertrag		
Zinserträge	0.00	0.01
Darlehenszinsen (aktiv)	4'630.11	0.00
	4'630.11	**0.01**
Finanzaufwand		
Bankzinsen und -spesen/Depotgebühren	288.85	866.20
Darlehenszinsen (passiv)	37'650.00	34'700.00
Kursdifferenzen	9'375.00	-12'938.66
	47'313.85	**22'627.54**
Ergebnis Finanzrechnung	**-42'683.74**	**-22'627.53**
Wertberichtigungen Darlehen/Beteiligungen	0.00	0.00
Periodenfremder Ertrag	0.00	0.00
Ergebnis vor Steuern	**-71'689.88**	**-52'968.06**
Steuern	1'200.00	420.00
Ergebnis nach Steuern	**-72'889.88**	**-53'388.06**